Navigation Links
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Date:6/13/2008

NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS) had been presented at the 13th Congress of the European Hematology Association (EHA) at the Bella Center in Copenhagen, Denmark. At the Congress, data were presented in a subset of 26 patients with high-risk MDS by French-American-British (FAB) Group criteria.

The median age of the patients in the subset was 71 years (range of 59-82 years). Twelve patients were diagnosed with refractory anemia with excess blasts (RAEB) and 9 patients were diagnosed with RAEB-t. Five patients were diagnosed with either chronic myelomonocytic leukemias (CMML) (3) or as unknown (2). Fifteen patients had intermediate cytogenetics and 11 had unfavorable cytogenetics. Sixteen of the patients were classified as Intermediate-2 risk by the International Prognostic Scoring System (IPSS) system (1.5-2.0), and 10 were classified as high risk (greater than or equal to 2.5).

Eight of the 26 patients had received prior treatment for their disease. Prior agents used included arsenic trioxide, thalidomide, Ara-C, imatinib mesylate, interferon, amifostine, melphalan, hydroxyurea and 5-azacitiadine.

The overall complete response rate was 38% (7 CR and 3 CRp). Three of 10 responders received prior treatment; 8 of the 10 responders received consolidation. The median (range) of overall survival for the entire patient group was 3.4 months (0.6-28.6) and the median (range) of overall survival for responders was 3.9 months (2.5-28.6).


'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  Genomic Health, Inc. (Nasdaq: ... , Chairman, Chief Executive Officer and President, will participate ... Conference at The New York Palace Hotel in ... at 11:30 am Eastern Time (ET). To ... conference call, go to the  Investor Relations  section of ...
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... 2014  CARsgen, a leader in the development of ... a variety of cancers, today announced the completion of ... China -based healthcare private equity fund.   ... the development of new therapeutics for liver, lung, stomach ... and Shanghai Renji Hospital, the company plans to initiate ...
Breaking Medicine Technology:Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2
... cell company,Neuralstem, Inc., (Amex: CUR ) announced ... a European patent EP0915968, covering the,"Isolation, Propagation and ... Central Nervous System of Mammals." The European patent,has ... Germany,Ireland, Spain, Sweden, Switzerland and the United Kingdom., ...
... In Migraine Pain ... 48 Hours Vs. Placebo, MENLO PARK, Calif., April ... from a clinical study of the company,s,novel investigational intranasal ... The placebo-controlled proof of concept study evaluated the ...
Cached Medicine Technology:Neuralstem Announces Issuance of Core Technology Patent in Europe 2ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment 2ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment 3
(Date:11/28/2014)... Mabel’s Labels , the market ... an award-winning company established by four moms, today announced ... Tricia Mumby have been honored with a 2014 RBC ... PROFIT Award for Excellence in Entrepreneurship. , All 4 ... Mumby) accepted the award on behalf of Mabel’s Labels ...
(Date:11/28/2014)... 28, 2014 UniWigs.com, a leader in the wig ... Friday to the next Monday. This promotion features: , ... 40 items up to 70% off (no coupon code needed), ... > Free shipping on orders over $49 , Visit http://www.uniwigs.com ... days from Nov. 28th to Dec. 1st and the first 100 ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 "Most of my ... me to use crutches," said an inventor from Findlay, Ohio. ... convenient way to support my foot, which inspired me to ... to offer a convenient way to support an injured foot. ... around. It eliminates the need for crutches. The design redistributes ...
(Date:11/28/2014)... November 28, 2014 Before that Thanksgiving meal ... preparing for the Christmas shopping season. Today, people will stand ... Black Friday, the biggest retail shopping day of the year. ... electronic device, New Albany dentist Dr. Ronald Receveur ... improve oral health and literally brighten a few smiles. , ...
(Date:11/28/2014)... 2014 Most of the people attending a ... at Lake Prince Woods retirement community found out ... sentimental value but wouldn’t have made the cut to be ... his expertise in decorative and folk art and his appearances ... about trends in buying and selling antiques. Broadly speaking ...
Breaking Medicine News(10 mins):Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 2Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 3Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 4Health News:Antiques Appraiser Sheds Light on "Treasures" 2
... Effective Means to Provide Health Care Access to Millions ... The National Patient Advocate Foundation (NPAF) - a national, ... of improved patient access to health care through public ... announced this month the election of four new Executive ...
... possibility of remote monitoring for chronically ill patients will ... and Australia have devised a decentralized system to avoid ... a forthcoming issue of the International Journal of ... range of chronic illnesses, including diabetes, high blood pressure, ...
... Health Care Reform, Received More Industry Contributions Than ... and pharmaceutical manufacturers contributed $5.5 million to the ... House of Representatives during the last two election ... reform dominated political discourse, according to the nonprofit, ...
... Petfinder.com and Merial Team Up to Ensure Animal Welfare ... 9 Petfinder.com, the largest online database of adoptable ... generators to 500 shelters and rescue groups nationwide with ... to the Paws program, a disaster preparedness initiative launched ...
... with chemo and radiation , , MONDAY, March 9 ... chemotherapy drug temozolomide and radiotherapy increases survival for glioblastoma ... improvement persists for up to five years, say Swiss ... aggressive form of primary brain tumor. For more than ...
... DALLAS, March 9 Inspired by Beryl Co-Founder Barry Spiegelman ... The Beryl Institute is hosting the second annual ... at Sky Creek Ranch Golf Club in Keller, Texas. To ... the tournament will be presented to UCLA,s Neuro-Oncology Program, ...
Cached Medicine News:Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 2Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 3Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 4Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 5Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 6Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 7Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 8Health News:Peer-to-peer heart monitoring 2Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 2Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 3Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 4Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 5Health News:Petfinder.com Foundation 'Rescues' 500 Shelters and Rescue Groups Nationwide with $1 Million Worth of Generators 2Health News:Combo Treatment for Aggressive Brain Tumor May Lengthen Life 2Health News:Think About It. Barry Spiegelman Memorial Golf Classic Benefits Brain Cancer Research 2
20 g MVR knife. Dimensions: 31.8 mm x 1.18 mm x 2.7 mm....
Full Handle Laseredge Spoon Blade Knife, 3.0 mm angled double bevel. Blade dimension: 11.0 mm (L) x 3.0 mm (W). Cut: 320....
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled double bevel. Blade tip dimension: 14.4 mm x 3.2 mm x 4.0 mm....
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Medicine Products: